Press "esc" to clear
Go to Advanced Search

Showing results

110 of 703
Chagasdiseaseguide.png

Article ID: 696494

New Kissing Bug Guide Published to Strengthen the Fight Against Chagas Disease

University of Texas Health Science Center at Houston

A guide to help battle a potentially fatal disease transferred by a blood-sucking insect called the kissing bug has been published by a task force led by The University of Texas Health Science Center at Houston (UTHealth).

Released:
21-Jun-2018 3:50 PM EDT
EXPERT AVAILABLE
Open in New Tab
Add to Favorites
Comment

Article ID: 696348

Houston Methodist receives additional $6 million Occidental Petroleum donation to enhance community patient care

Houston Methodist

A Houston Methodist program that provides specialty patient care to uninsured and underserved patients received another multi-million dollar gift from Occidental Petroleum Corporation.

Released:
20-Jun-2018 8:30 AM EDT
EXPERT AVAILABLE
Open in New Tab
Add to Favorites
Comment
BassFamilyphoto2..jpg

Article ID: 696333

If Only…

Houston Methodist

The American Cancer Society's recent recommendations for changing the colorectal cancer screening age to 45 from age 50 had significant meaning for a Magnolia, Texas woman.

Released:
19-Jun-2018 3:05 PM EDT
EXPERT AVAILABLE
Open in New Tab
Add to Favorites
Comment
john_mendelsohn.jpg

Article ID: 696283

Mendelsohn shares Tang Prize for leadership in developing targeted therapy

University of Texas M. D. Anderson Cancer Center

Targeted cancer therapy pioneer John Mendelsohn, M.D., researcher and former president of The University of Texas MD Anderson Cancer Center, will share the 2018 Tang Prize in Biopharmaceutical Science for his leadership in developing antibodies to block cancer-promoting growth factor receptors on the surface of cancer cells.

Released:
18-Jun-2018 11:00 PM EDT
EXPERT AVAILABLE
Open in New Tab
Add to Favorites
Comment
Cortes.jpg
  • Embargo expired:
    16-Jun-2018 2:30 AM EDT

Article ID: 696175

Phase III study shows quizartinib prolongs overall survival for patients with deadly type of relapsed or refractory AML

University of Texas M. D. Anderson Cancer Center

A study led by The University of Texas MD Anderson Cancer Center revealed that the investigational drug quizartinib prolonged overall survival for patients with a deadly form of acute myeloid leukemia (AML) linked to a genetic mutation called FMS-like internal tandem duplications (FLT3-ITD).

Released:
15-Jun-2018 10:00 AM EDT
EXPERT AVAILABLE
Open in New Tab
Add to Favorites
Comment
148380_Sharma_P11.jpg

Article ID: 696198

Researchers Find Combination Can Enhance Ipilimumab Immunotherapy

University of Texas M. D. Anderson Cancer Center

Using a targeted therapy to block a protein that suppresses T cell activity could improve cancer treatment with immune checkpoint inhibitors, researchers at The University of Texas MD Anderson Cancer Center report today in the Journal of Clinical Investigation.

Released:
15-Jun-2018 4:05 PM EDT
EXPERT AVAILABLE
Open in New Tab
Add to Favorites
Comment

Article ID: 696082

MD Anderson, Houston Methodist Scientists Detect New Ovarian Cancer Target

Houston Methodist

Researchers at Houston Methodist Research Institute and The University of Texas MD Anderson Cancer Center have found a prescription drug, Calcitriol, approved by the Food and Drug Administration for the treatment of calcium deficiency and kidney diseases, may increase the likelihood of surviving ovarian cancer. Their preclinical research was reported in the Journal of the National Cancer Institute.

Released:
13-Jun-2018 1:00 PM EDT
EXPERT AVAILABLE
Open in New Tab
Add to Favorites
Comment
LaurenByers.jpg
  • Embargo expired:
    11-Jun-2018 4:00 PM EDT

Article ID: 695948

PARP Inhibitor Improves Overall Response Rates in Small Cell Lung Cancer Patients

University of Texas M. D. Anderson Cancer Center

In a randomized, Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center, adding the PARP inhibitor veliparib to a standard chemotherapy agent improved overall response rates (ORR) in patients with small cell lung cancer (SCLC). Researchers also identified a select group of patients – those whose tumors expressed SLFN11— who also saw a progression-free survival (PFS) and overall survival (OS) benefit, suggesting a promising biomarker for the PARP-inhibitor sensitivity in SCLC.

Released:
11-Jun-2018 3:20 PM EDT
EXPERT AVAILABLE
Open in New Tab
Add to Favorites
Comment
Marszalek.jpg
  • Embargo expired:
    11-Jun-2018 11:00 AM EDT

Article ID: 695886

MD Anderson Therapeutics Discovery team identifies and advances a drug that targets metabolic vulnerability and impairs cancer cell growth and survival

University of Texas M. D. Anderson Cancer Center

A drug discovered and advanced by The University of Texas MD Anderson Cancer Center’s Institute for Applied Cancer Science (IACS) and the Center for Co-Clinical Trials (CCCT) inhibits a vital metabolic process required for cancer cells’ growth and survival.

Released:
8-Jun-2018 6:05 PM EDT
EXPERT AVAILABLE
Open in New Tab
Add to Favorites
Comment
Thompson-Zimmerman1.jpg

Article ID: 695697

Practicing medicine is in the blood for McGovern Medical School graduate

University of Texas Health Science Center at Houston

When budding doctor Rebecca Thompson graduated from McGovern Medical School at The University of Texas Health Science Center at Houston (UTHealth) May 18, she furthered a four-generation-strong family legacy.

Released:
8-Jun-2018 11:25 AM EDT
EXPERT AVAILABLE
Open in New Tab
Add to Favorites
Comment

Education


Showing results

110 of 703





Chat now!